Cleveland BioLabs is a biotechnology business based in the US. Cleveland BioLabs shares (CBLI) are listed on the NASDAQ and all prices are listed in US Dollars. Cleveland BioLabs employs 18 staff and has a trailing 12-month revenue of around $106,900.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| 52-week range | $0.00 - $0.00 |
|---|---|
| 50-day moving average | $3.62 |
| 200-day moving average | $3.62 |
| Wall St. target price | $2.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.74 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
| Revenue TTM | $106,900 |
|---|---|
| Gross profit TTM | $-428,128 |
| Return on assets TTM | -20.33% |
| Return on equity TTM | -31.86% |
| Profit margin | 0% |
| Book value | $0.60 |
| Market Capitalization | $49.1 million |
TTM: trailing 12 months
We're not expecting Cleveland BioLabs to pay a dividend over the next 12 months.
Cleveland BioLabs's shares were split on a 1:20 basis on 27 January 2015 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cleveland BioLabs shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Cleveland BioLabs shares which in turn could have impacted Cleveland BioLabs's share price.
Over the last 12 months, Cleveland BioLabs's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cleveland BioLabs's is 0.6837. This would suggest that Cleveland BioLabs's shares are less volatile than average (for this exchange).
Cytocom, Inc. , a clinical-stage biopharmaceutical company, develops novel small molecule immunotherapies targeting cancer, autoimmune, inflammatory, and infectious diseases. Its platform, Advanced Immunomodulating Multi-receptor System (AIMS), offers noroxymorphone analogs multi-receptor modulating therapies and proenkephalin analogs multi-receptor modulating therapies. The company also has various clinical-stage development programs, including CYTO-200 for Crohn's disease, fibromyalgia, multiple sclerosis, and covid-19; CYTO-400 for hepatocellular and pancreatic cancer; and CYTO-600 for acute radiation syndrome, advanced solid tumors, and vaccine adjuvant. Cytocom, Inc. has a collaboration agreement with the La Jolla Institute for Immunology for research and development of new immune-modulating agents targeting toll-like receptors for the treatment of cancer, infectious, autoimmune, and chronic inflammatory diseases. The company is based in Fort Collins, Colorado.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Stock lending allows investors to loan out their existing stocks, although it has both advantages and disadvantages.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.